Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate

Andrea Bianchini1, Maria Loiarro, Pamela Bielli

  • 1Department of Public Health and Cell Biology, University of Rome Tor Vergata, Rome, Italy.

Carcinogenesis
|September 24, 2008
PubMed

Insights

Prostate cancer cells rely on AKT/mTOR and MAPK/MNK pathways for growth. Inhibiting these pathways, particularly MNK, impacts messenger RNA translation and cell proliferation, offering therapeutic potential.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Prostate carcinomas (PCas) exhibit dysregulation of phosphatidyl inositol trisphosphate kinase/AKT/mammalian target of rapamycin (mTOR) and RAS/mitogen-activated protein kinase (MAPK)/MNK pathways.
  • These pathway alterations lead to aberrant messenger RNA (mRNA) translation, impacting cancer cell behavior.

Purpose of the Study:

  • To investigate the distinct roles of AKT/mTOR and MAPK/MNK pathways in regulating mRNA translation and proliferation in prostate cancer cells.
  • To determine the impact of inhibiting these pathways on key cellular processes.

Main Methods:

  • Utilized prostate cancer cell lines (DU145, PC3, LNCaP) with varying PTEN and AKT/mTOR activity.
  • Employed MNK inhibitors, rapamycin (mTOR inhibitor), serum depletion, and pull-down assays to assess translational control.
  • Performed microarray analysis to identify affected mRNAs and assessed cell proliferation and cell cycle progression.

Main Results:

  • MNK pathway activity correlated with eIF4E phosphorylation in PTEN-expressing cells.
  • Inhibition of MNKs reduced polysomal recruitment of terminal oligopyrimidine mRNAs (TOP mRNAs).
  • Combined MNK and mTOR inhibition showed additive effects on TOP mRNA translation and protein synthesis, suppressing cell cycle progression.

Conclusions:

  • A balance between AKT/mTOR and MAPK/MNK pathways is crucial for maintaining mRNA translation, ribosome biogenesis, and proliferation in prostate cancer.
  • Targeting the MAPK/MNK pathway, especially in PTEN-expressing cells, and combining it with mTOR inhibition, presents a promising therapeutic strategy for prostate cancer.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...